Industry News
Long-term hormonal therapy in intermediate-risk prostate cancer patients does not improve overall survival
Sep 25, 2013
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation On... Read More
Patient-reported outcomes provide valuable insight regarding quality of life for patients with non-small cell lung cancer
Sep 25, 2013
An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented at the American Society for Radiation Oncology's ... Read More
New treatments aim to combat renal cell cancer and melanoma
Sep 25, 2013
Renal cell cancer vaccines Immatics Biotechnologies' cancer vaccine IMA901 is currently in phase III trials for the first-line treatment of metastatic renal cell cancer. The drug, which was shown to have a positive safety profile in its single-arm Phase II trial, is expected to gain approval in the US and five major EU markets* by 2015... Read More
In intermediate risk prostate cancer, fewer weeks of hormone therapy before radiation reduces side effects
Sep 25, 2013
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting... Read More
Married cancer patients 'likely to live longer'
Sep 25, 2013
People who are married when they are diagnosed with cancer are more likely to live longer, compared with those who are unmarried. This is according to a new study published in the Journal of Clinical Oncology... Read More
New patient-focused five minute Herceptin® (trastuzumab) jab given green light by regulators & NHS England
Sep 25, 2013
Patients with a very aggressive form of breast cancer known as HER2-positive, could now benefit from a new faster, more efficient delivery method of Herceptin. The subcutaneous (SC) injection, given just beneath the skin, can be completed in 2-5 minutes, compared to the traditional, relatively time-consuming 30-90 minute intravenous (IV) infusion... Read More
Task Force issues final recommendations on medications for risk reduction of primary breast cancer in women
Sep 25, 2013
The United States Preventive Services Task Force (USPSTF) recommends against using medications such as tamoxifen or raloxifene for reducing the risk of primary breast cancer in average risk women, as the risks associated with these medications outweigh the potential benefits... Read More
Some pediatric surgeries do not require preoperative blood typing
Sep 25, 2013
Certain pediatric surgeries carry such low risk of serious blood loss that clinicians can safely forgo expensive blood typing and blood stocking before such procedures, suggest the results of a small study by researchers at the Johns Hopkins Children's Center... Read More
In intermediate risk prostate cancer, fewer weeks of hormone therapy before radiation reduces side effects
Sep 25, 2013
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting... Read More
Human brain tumor cells destroyed in mouse model
Sep 25, 2013
Working with mice, Johns Hopkins researchers have discovered that weeks of treatment with a repurposed FDA-approved drug halted the growth of - and ultimately left no detectable trace of - brain tumor cells taken from adult human patients... Read More
Previous Page Next Page